Skip to main content
. 2020 May 19;24:12–22. doi: 10.1016/j.jot.2020.04.008

Fig. 5.

Fig. 5

Defactinib inhibits the activation of FAK-Grb2-MARK in MSCs from subchondral bone during OA development. (A and B) Immunostaining and quantification of p-FAK in MSCs from subchondral bone of the sham controls, vehicle-treated ACLT mice, and defactinib-treated ACLT mice. Scale bar, 20 μm n = 5 per group. (C and D) Western blotting of p-FAK, p-Grb2, and p-MAPK in MSCs from the different groups. Sham = sham controls; ACLT + Veh = vehicle-treated ACLT mice; ACLT + Def = defactinib-treated ACLT mice. ∗p < 0.05 and ∗∗p < 0.01 compared to sham. #p < 0.05 and ##p < 0.01 compared to vehicle.